Less Bleeding by Omitting Aspirin in Non-ST-segment Elevation Acute Coronary Syndrome Patients

Status

Active, not recruiting

Phases

Phase 4

Study type

Interventional

Source

EU CTIS

Registry ID

CTIS2023-504360-42-00

Enrollment

3090

Registered

2023-04-03

Start date

2022-05-13

Completion date

Unknown

Last updated

2024-12-02

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Non-ST-segment elevation acute coronary syndrome

Brief summary

Major or minor bleeding defined as Bleeding Academic Research Consortium (BARC) type 2, 3 or 5 bleeding at 12 months, Composite of all-cause mortality, myocardial infarction, and stroke at 12 months

Interventions

DRUGAcetylsalicylzuur Cardio Aurobindo 80 mg

DRUGdispergeerbare tabletten.

Eligibility

Sex/Gender

All

Age

18 Years to No maximum

Design outcomes

Primary

Measure	Time frame
Major or minor bleeding defined as Bleeding Academic Research Consortium (BARC) type 2, 3 or 5 bleeding at 12 months, Composite of all-cause mortality, myocardial infarction, and stroke at 12 months	—

Countries

Belgium, Netherlands

Outcome results

None listed

Source: EU CTIS · Data processed: Feb 4, 2026